- Home
- DHY vs CDXS Comparison
DHY vs CDXS Comparison
Compare DHY & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- CDXS
- Stock Information
- Founded
- DHY 1998
- CDXS 2002
- Country
- DHY United States
- CDXS United States
- Employees
- DHY N/A
- CDXS N/A
- Industry
- DHY Finance/Investors Services
- CDXS Major Chemicals
- Sector
- DHY Finance
- CDXS Industrials
- Exchange
- DHY Nasdaq
- CDXS Nasdaq
- Market Cap
- DHY 213.4M
- CDXS 216.6M
- IPO Year
- DHY N/A
- CDXS 2010
- Fundamental
- Price
- DHY $2.11
- CDXS $2.51
- Analyst Decision
- DHY
- CDXS Buy
- Analyst Count
- DHY 0
- CDXS 2
- Target Price
- DHY N/A
- CDXS $11.00
- AVG Volume (30 Days)
- DHY 569.1K
- CDXS 565.4K
- Earning Date
- DHY 01-01-0001
- CDXS 10-30-2025
- Dividend Yield
- DHY 9.10%
- CDXS N/A
- EPS Growth
- DHY N/A
- CDXS N/A
- EPS
- DHY N/A
- CDXS N/A
- Revenue
- DHY N/A
- CDXS $57,164,000.00
- Revenue This Year
- DHY N/A
- CDXS $12.88
- Revenue Next Year
- DHY N/A
- CDXS $21.64
- P/E Ratio
- DHY N/A
- CDXS N/A
- Revenue Growth
- DHY N/A
- CDXS N/A
- 52 Week Low
- DHY $1.77
- CDXS $1.90
- 52 Week High
- DHY $2.08
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- DHY 58.47
- CDXS 48.49
- Support Level
- DHY $2.04
- CDXS $2.51
- Resistance Level
- DHY $2.10
- CDXS $2.93
- Average True Range (ATR)
- DHY 0.02
- CDXS 0.14
- MACD
- DHY 0.00
- CDXS 0.02
- Stochastic Oscillator
- DHY 93.75
- CDXS 26.37
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.